A R T I C L E I N F O
Through the depletion of Trp and the generation of kynurenines, IDO1 represents a key regulator of the immune responses involved in physiologic homeostasis as well as in neoplastic and autoimmune pathologies. The IDO1 enzyme has been described as an important immune checkpoint to be targeted by catalytic inhibitors in the treatment of cancer. In contrast, a defective expression/activity of the enzyme has been demonstrated in autoimmune diseases. Beside its catalytic activity, the IDO1 protein is endowed with an additional function associated with the presence of two immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, once phosphorylated, bind SHP phosphatases and mediate a long-term immunoregulatory activity of IDO1. Herein, we report the screening of a focused library of molecules bearing a propanol core by a protocol combining microscale thermophoresis (MST) analysis and a cellular assay. As a result, the combined screening identified a 2-propanolol analogue, VIS351, as the first potent activator of the ITIM-mediated function of the IDO1 enzyme. VIS351 displayed a good dissociation constant (Kd = 1.90 μM) for IDO1 and a moderate cellular inhibitor activity (IC 50 = 11.463 μM), although it did not show any catalytic inhibition of the recombinant IDO1 enzyme. Because we previously demonstrated that the enzymatic and non-enzymatic (i.e., ITIM-mediated) functions of IDO1 reside in different conformations of the protein, we hypothesized that in the cellular system VIS351 may shift the dynamic conformational balance towards the ITIM-favoring folding of IDO1, resulting in the activation of the signaling rather than catalytic activity of IDO1. We demonstrated that VIS351 activated the ITIM-mediated signaling of IDO1 also in mouse plasmacytoid dendritic cells, conferring those cells an immunosuppressive phenotype detectable in vivo. Thus the manuscript describes for the first time a small molecule as a positive modulator of IDO1 signaling function, paving the basis for an innovative approach to develop first-in-class drugs acting on the IDO1 target.
Introduction
Indoleamine 2,3 dioxygenase 1 (IDO1) is a metabolic enzyme that catalyzes the conversion of the essential amino acid L-tryptophan (Trp) into a series of immunoactive catabolites, collectively known as kynurenines. The IDO1 enzyme has been largely described as a powerful regulator of the immune responses, since IDO1, through the depletion of Trp and the generation of bioactive metabolites can create an extracellular milieu that promotes immune tolerance. IDO1 activity has been demonstrated to inhibit effector T cells, favor regulatory T cell differentiation and program dendritic cells (DCs) and macrophages toward an immunosuppressive phenotype [1] [2] [3] . The IDO1 enzyme plays a physiological role in guaranteeing several immune privileged sites. Human studies indicated a constitutive IDO1 expression in the placenta, eye, and pancreas [4] [5] [6] . Moreover, IDO1 is involved in the pathogenesis and severity of different disease conditions, including chronic inflammation, infectious disease, allergic and autoimmune disorders, transplantation, neuropathology, and cancer [7] [8] [9] [10] [11] . The enzyme has been recognized as an important immune checkpoint for the development of catalytic inhibitors in oncology [12] . In contrast, a defective expression/activity of the enzyme has been described in autoimmune diseases [13] [14] [15] and thus drugs capable of enhancing IDO1 immunoregulatory mechanisms are demanding.
IDO1 exerts its immunoregulatory effects via several molecular mechanisms, including the deprivation of Trp and its conversion into Lkynurenine (Kyn), a ligand of the aryl hydrocarbon receptor (AhR) [16, 17] and the following conversion into down-stream bioactive Trp catabolites [1, 18, 19] . Moreover, IDO1 is endowed with non-enzymatic activity that involves tyrosine phosphorylation of the immunoreceptor tyrosine-based inhibitory motifs (ITIM) 1 and 2 present in its noncatalytic, small domain. Phosphorylated IDO1 ITIMs generate in IDO1 two docking sites for Src homology 2 (SH2)-containing proteins, such as the suppressor of cytokine signaling (SOCS)3 and tyrosine phosphatases SHP-1 and SHP-2. The association with either partners (i.e., SOCS3 or SHP phosphatases) can modulate the enzyme half-life toward an opposite fate. In an IL-6-driven inflammatory context, SOCS3 becomes highly expressed in dendritic cells (DCs) and shortens IDO1 half-life by accelerating its proteasomal degradation. By contrast, the association of SHP phosphatases to IDO1 prolongs the enzyme half-life through the activation of a feedforward loop that sustains the de novo synthesis of the enzyme and TGF-β, a required condition for restraining autoimmunity and chronic diseases [20] [21] [22] . IDO1 mutants, mimicking the stable phosphorylation of ITIMs, show a complete loss of catalytic activity, a result that might be traced to a major change in protein folding. Despite the loss of catalytic activity, IDO1 mutants maintain their ability to trigger ITIM-related functions [23] . Thus the enzymatic and non-enzymatic functions of IDO1 may reside in different conformations of the protein and could be mutually exclusive, suggesting a dynamic balance between the catalytically active and the ITIM-favoring conformations of IDO1, occurring in cells. In the current manuscript, we describe a screening approach that led us to identify for the first time a positive modulator of the ITIM-function -rather than the catalytic activity -of the IDO1 protein.
Materials and methods

Animals and reagents
Female wild-type C57BL/6 mice of 6-wks of age were purchased from Charles River Breeding Laboratories Italia (Milan, Italy) and female IDO1-deficient (Ido1 −/− ) C57BL/6 mice were from Jackson Laboratories (ME, USA) and bred at Charles River Breeding Laboratories. All animals were housed and fed under specific pathogenfree conditions in the animal facility of the University of Perugia. All in vivo studies were in compliance with National (Italian Animal Welfare Assurance A-3143-01) and Perugia University Animal Care and Use Committee guidelines. Cycloheximide and DMSO were purchased from Sigma-Aldrich (MO, USA). The H-2D b -restricted HY peptide (WMHH-NMDLI) -containing the immunodominant epitope of male mousespecific minor transplantation antigen -was synthesized by BioFab Research (Rome, Italy). Recombinant human IDO1 (rhIDO1) (residues 1-403) was purchased from Giotto Biotech S.r.l. (Firenze, Italy). All tested compounds were purchased from Life Chemicals Europe (Munich, Germany). The NLG919 analogue was purchased from Selleckchem (Huston, TX, USA).
Microscale thermophoresis (MST)
MST experiments were carried out using the Monolith NT.115 instrument (NanoTemper Techonologies, Munich, Germany). The assay is based on the use of 16 capillary tubes that are filled with a fluorescent dye-labeled target protein and a serial titration of unlabeled ligand. Capillary tubes are then illuminated with an infrared laser that generates a temperature gradient. The protein/ligand complex migrates along this gradient causing changes in the observed fluorescence. These signals are used to generate a binding curve as a function of ligand concentration that is then analyzed to assess the K d value [24] . As previously reported [25] , fluorescence labeling of rhIDO1 was performed following the manufacturer's instructions for N-hydroxysuccinimide (NHS) coupling of the dye NT647 to lysine residues. The stability of NT647-rhIDO1 and unlabeled rhIDO1 protein in the experimental conditions was checked using circular dichroism, as previously reported [25] . Binding experiments were carried out using premium-coated capillaries and MST buffer containing 2% DMSO and 2 mM DTT. Compound stocks (50 mM) in DMSO were diluted in the assay buffer to reach the highest soluble concentration (1 mM 
Docking studies
The crystal structure of IDO1 in complex with the NLG919 analogue (PDB code: 5EK3, resolution = 2.20 Å) [27] was downloaded from the Protein Data Bank [28] , and its chain A was prepared by adding hydrogen atoms with relative ionization states at pH 7.0, using the Protein Preparation Wizard implemented in Maestro v10.1 (Maestro, version 10.1, Schrödinger, LLC, New York, NY, 2015). The unsolved loop 361-379 was reconstructed with Prime v3.9 (Prime, version 3.9, Schrödinger, LLC, New York, NY, 2015), while the formal charge of the iron was set as FeIII. The molecular structure of VIS351 was refined with LigPrep v3.3, generating all ionization and tautomer states at pH 7 ± 2. Docking studies were carried out using Glide v6.6 with the default extra-precision (XP) method combined with an expanded sampling mode (Glide, version 6.6, Schrödinger, LLC, New York, NY, 2015). The number of poses to keep for the initial phase of docking was set to 50.000 in a scoring window of 500 kcal/mol. The energy minimization for the best 800 poses was carried out performing 10.000 maximum number of steps. The docking grid was defined with the centre located on the center of mass of the co-crystallized ligand in 5EK3, and the inner grid box sized at 10 × 10 × 10 Å.
Cellular assays
Cells of P1.HTR, a highly transfectable clonal variant of mouse mastocytoma P815 [29] , were transfected by electroporation with plasmid constructs coding for mouse IDO1 (P1.IDO1) or tryptophan 2,3-dioxygenase (P1.TDO). Stable transfectant cell lines were obtained by puromycin selection. Both cell lines were cultured in Iscove's Modified Dulbecco's Medium (Gibco, Invitrogen CA, USA) supplemented with 10% FCS (Gibco, Invitrogen CA, USA), 1 mM glutamine (Gibco, Invitrogen CA, USA) and penicillin/streptomycin (Gibco, Invitrogen CA, USA) at 37°C in a humidified 7% CO 2 incubator. In every cellular assay, cell lines were used at a passage number not exceeding the 10th. For evaluating the inhibition of mouse IDO1 in a cellular context, 
LDH cytotoxicity assay
Molecule-dependent cytotoxicity was estimated using the LDHCytotoxicity Assay Kit (Abcam, Cambridge, UK), according to the manufacturer's instructions. 1 × 10 4 P1.IDO1 cells were plated in a flatbottomed 96-well plate containing a final volume of 200 μl of medium and 2-fold dilutions in the range of 1.25-80.00 μM concentration of the molecules. P1.IDO1 cells incubated with DMSO alone, the vehicle used to dilute the molecules, served as spontaneous LDH activity controls. For the maximum LDH activity control, P1.IDO1 cells were incubated with medium containing 1% TritonX-100 (Sigma-Aldrich, MO, USA). In all conditions, cells were incubated in triplicate at 37°C, 7% CO 2 . After 16 h, an aliquot (100 μl) of each sample was transferred into a new 96-well plate, mixed with 100 μl of Reaction Mixture and incubated for 30 min at RT in the dark. Absorbance values at 490 nm and 620 nm were measured using a Tecan Infinite M200 reader (Mannedorf, Switzerland). The LDH activity was calculated by subtracting the 620 nm absorbance value (due to plate absorbance) from the 490 nm absorbance. Cell viability percentage was shown as the reciprocal of the amount of LDH released by the cell sample.
Enzymatic assay
IDO1 enzymatic assay was carried out according to the protocol described previously [30] . In brief, compounds or DMSO, as control, were mixed in a final volume of 200 μl of a standard reaction mixture containing 50 mM potassium phosphate buffer (pH 6.5), 20 mM ascorbic acid (neutralized with NaOH), 200 μg/mL catalase, 10 μM methylene blue, 20 μM Trp (Sigma-Aldrich, MO, USA) and 0.125 μg rhIDO1 protein (Giotto Biotech S.r.l., Firenze). To estimate enzymatic IC 50 , VIS351 and NLG919 (as reference inhibitor) were seven times 10-fold diluted, starting from the highest soluble concentration (2 mM). The reaction was carried out at 37°C for 60 min and stopped by the addition of 40 μl HClO 4 (Sigma-Aldrich, MO, USA). To complete the hydrolysis of N-formyl-kynurenine into Kyn, samples were heated at 65°C for 15 min and then centrifuged at 12.000 rpm for 7 min at RT. The supernatant (200 μl) was transferred into a new Eppendorf tube and used for Kyn analysis. Each enzymatic assay was conducted in triplicate and repeated three times. Results are represented as the mean ± standard deviation of the Kyn FC, i.e., the ratio between Kyn concentration in samples with compounds and control (i.e., DMSO alone).
IDO1 protein degradation analysis
P1.IDO1 cells (2 × 10 5 ) were pre-treated with 10 μg/ml of the protein synthesis inhibitor cycloheximide in a final volume of 400 μl for 30 min at 37°C. Then, cells were stimulated with VIS351 (30 μM) or DMSO as control, for 0, 1, 3 and 6 h and immediately lysed for IDO1 protein expression analysis by immunoblotting. Protein lysates were subjected to SDS-PAGE and electro-blotted onto 0.2 µm nitrocellulose membranes (Bio-Rad, CA, USA). Membranes were blocked with 5% non-fat dried milk in TBS and probed with a rabbit polyclonal antibody specific for mouse IDO1, raised in our laboratory [23] in combination with an appropriate horseradish peroxidase-conjugated antibody (Millipore, MA, USA), followed by enhanced chemiluminescence (ECL) (Bio-Rad, CA, USA). Anti-β-tubulin (Sigma-Aldrich, MO, USA) was used as a normalizer. In each experiment, the densitometric analysis of specific signals was performed by ChemiDoc XRS + Imagin System (Bio-Rad, CA, USA), within a linear range of blot exposure, selecting the two lowest exposure times required for detecting signals. Results of the densitometric analysis were represented as the mean ± SD of three different Western blot analyses. For each sample, the ratio of normalized IDO1 protein at each time point over the time 0 was shown.
Kynurenine and cytokines measurements
Detection of Kyn concentrations was performed by using a Perkin Elmer, series 200 HPLC instrument (MA, USA). A Kinetex ® C18 column (250 × 4.6 mm, 5 μm, 100 Å; Phenomenex, USA), maintained at the temperature of 25°C and pressure of 1800 PSI, was used. A sample volume of 300 µl was injected and eluted by a mobile phase containing 10 mM NaH 2 PO 4 pH 3.0 (99%) and methanol (1%) (Sigma-Aldrich, MO, USA), with a flow rate of 1 ml/min. Kyn was detected at 360 nm by an UV detector. The software TURBOCHROM 4 was used for evaluating the concentration of Kyn in samples by mean of a calibration curve. The detection limit of the analysis was 0.05 μM. Mouse TGF-β (Affymetrix, Santa Clara, CA, USA), IL-6 (eBioscience -Termo Fisher Scientific, MS, USA) and IL-10 (Life Technologies, CA, USA) levels were measured in culture supernatants by specific kit ELISA, according to the manufacturer's recommendations.
Phosphatase assay
P1.IDO1 cells were pre-incubated for 4 h with VIS351 (30 μM) or DMSO as control, before assessing the phosphatase activity associated with the IDO1 protein. For each condition, the IDO1 protein was immunoprecipitated from 6 x 10 6 cells lysed in 400 μl of Lysis Buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet P-40 and a cocktail of protease inhibitors). The IDO1 protein was immunoprecipitated overnight at 4°C by a specific polyclonal rabbit antibody raised in our lab, followed by addition of Protein G-Sepharose (Sigma-Aldrich, MO, USA) for 2 h. The phosphatase activity associated with immunoprecipitated IDO1 was assessed by a specific kit purchased from Promega (WI, USA), according to the manufacturer's instructions.
DC purification and skin test assay
All purification procedures of splenic wild-type (WT) or Ido1 −/− pDCs and CD8 − DCs (hereafter referred to as cDCs, for conventional DCs) were conducted as previously described in [21, 31] . A skin test assay was used for measurements of major histocompatibility complex class I-restricted delayed-type hypersensitivity (DTH) responses to the HY peptide in C57BL/6 female recipient mice [21, 32] . For in vivo immunization, 3 × 10 5 peptide-loaded cDCs, combined with a minority fraction (5%) of peptide-loaded WT or Ido1 −/− pDCs, were injected subcutaneously into recipient mice. After two weeks, mice were challenged intrafootpad with the HY peptide in the absence of DCs (experimental footpad) or with vehicle alone (control counterpart). Twenty-four hours later, mice were sacrificed, footpads were removed and the change in the weight of the peptide-injected footpad over that of the vehicle-injected counterpart (i.e., internal control) was measured. A significant increase in mean weight of the experimental over the control footpads will then demonstrate and quantify any delayedtype, antigen-specific hypersensitivity response. Results are represented as the mean weight ± SD of the experimental footpads over that of control, vehicle-injected counterparts. The significance marked on each condition is referred to a two-tailed paired t test (experimental vs control footpads) for each group of mice (n = 6). 
Flow cytometry
Real-time PCR analysis
Expression of Ido1, Tgfb1, Ptpn6, Ptpn11 and Socs3 genes was analyzed by Real-Time PCR, as described [21] using the specific primers reported in Table 1 . Real time PCR assays were performed using Stratagene Mx3005P (Agilent Technologies, CA, USA). The cycling program consisted of a pre-incubation of 10 min at 95°C followed by 40 cycles consisting of 10 s at 95°C, 30 s at 60°C and 1 s at 72°C. mRNA levels were normalized to the expression of the Gapdh housekeeping gene. The Ct number was measured using the MxPro-Mx3005P software (Agilent Technologies, CA, USA). Values were expressed as the ratio of Gapdhnormalized transcript expression of VIS351 treated-pDCs to Gapdhnormalized transcript expression of untreated pDCs.
Results
Analogue-based screening
We previously reported a fragment-based screening campaign to identify building blocks as starting points for the development of IDO1 inhibitors. As a result, we disclosed 14 fragments binding IDO1 with different dissociation constants, and belonging to different chemical classes [25] . In particular, one active fragment bearing a propanol scaffold (1) was found as structurally similar to the NLG919 analogue (2) (Fig. 1) . Remarkably, this fragment was devoid of a chemical group able to coordinate the iron atom of the heme cofactor, as represented in the crystal structure of 2 in complex with IDO1 (Fig. 2) . Very few IDO1 inhibitors binding the enzyme without a direct interaction with the iron heme have been reported in literature [25] . The most advanced compounds of this kind include D-1-methyl-tryptophan (3) and PF-06840003 (4) (Fig. 1) , which are in clinical trials as single agent therapy (e.g., NCT00567931 and NCT02764151) or in combination therapy with cytotoxic agents, vaccines or checkpoint inhibitors (e.g., NCT01191216, NCT01042535 and NCT02073123). Recently, Nelp et al. described a promising class of compounds that target the apo-form of IDO1 and inhibit the enzyme in a specific and effective manner [33] .
With the aim of further exploring functional activities of this class of compounds, we firstly embarked on a hit-to-lead optimization strategy, expanding the series of IDO1 ligands endowed with a central propanol scaffold. Accordingly, analogue-based searches around compound 1 (K d = 96.7 µM) were carried out using commercial compound libraries and a total of 20 molecules (5-24) (Fig. 3 ) bearing a propanol core was purchased and used for MST binding experiments against IDO1. Based on the results reported in Table 2 , inspection of dissociation constants (K d ) values revealed that four compounds (13, 14, 21, 22) bind IDO1 with a K d in the low micromolar range (i.e., < 10 µM). In particular, a comparative analysis of the binding efficiency index (BEI) suggested compound 14 as identical to the NLG919 analogue (2) in terms of efficiency of ligand/protein interaction [26] , despite the former lacks any hydrogen bond and/or coordinative interaction to the heme group.
Combining MST to cellular screening
In order to achieve early information on the efficacy of the 20 molecules (5-24) in a cellular system, the MST approach was combined with a cellular assay for selecting those molecules featured by a good dissociation constant (K d < 10 μM) and the ability to permeate the cell. Specifically, the 20 compounds (5-24), previously evaluated in MST experiments , were also tested for their ability to inhibit the conversion of Trp into Kyn in the mastocytoma cell line P1.IDO1, stably expressing the mouse protein IDO1 (mIDO1), as described [25] . The reference molecule used in the cellular screening was represented by the NLG919 analogue (2) . Previous published data demonstrated an excellent correlation between results obtained from mIDO1 expressed by a cell system and the human IDO1 (hIDO1) in cell-free assays [34, 35] , since mouse and human sequences of IDO1 share a 61% of identity and, most importantly, both catalytic domain and the ITIM sequences of human and mouse proteins are highly conserved [22, 36] . Each compound, included the reference molecule NLG919, was tested in the cellular assay at the single concentration of 30 μM for 16 h and Kyn secretion in cell culture supernatants was detected by HPLC analysis.
As expected, NLG919 abrogated Kyn production with a nearly 90% of inhibition. The majority of compounds that had shown a K d > 10 μM revealed an inhibitory activity below 50%. In spite of their high K d value, molecules 10 and 16 (respectively, K d > 1,000 μM and K d = 59.5 μM) resulted in an inhibitory activity of nearly 65%. Among the four compounds (13, 14, 21, 22 ) with a K d < 10 μM, only molecules 14 and 21 demonstrated an inhibitory activity above 50%, while molecules 13 and 22 showed an inhibitory activity below 40% (Fig. 4A) .
Based on the usefulness of a combined screening coming from both a cell-free (i.e., MST) and a cellular assay, we computed a combined screening (CS) score for each compound as the ratio between the inhibitory activity (%) in the cell assay and the K d value observed in MST. As a result, a higher inhibitory activity combined with a lower K d value will result in a high CS score. Estimation of the CS score confirmed Table 1 Primer sequences used in the study.
Gene
Primer sequence
Abbreviations: F, forward; R, reverse.
E. Albini et al. Biochemical Pharmacology 158 (2018) 286-297
compounds 14 and 21 as those molecules having the highest score among the analyzed analogues, even much higher than that of the reference compound NLG919 (Fig. 4B) . In contrast, molecules 13 and 22 (K d = 6.3 μM and K d = 4.0 μM, respectively), resulted in a very low CS score that led us to discard them from further analysis. Overall, the above combined screening corroborated the validity of the method and allowed us to select the compounds 14 and 21, both characterized by a good K d and efficacy in the cell system expressing the target protein.
Cellular and enzymatic IC 50 determination
In order to exclude false positives due to a cytotoxic effect of the molecules, we firstly analyzed molecules 14 and 21 to exclude that the decreased Kyn levels secreted after cell incubation could be caused by a cytotoxic effect. To this purpose, we used the LDH-cytotoxicity assay that measures the activity of the LDH enzyme released from damaged cells. By using seven 2-fold dilutions in the 1.25-80.00 μM concentration range, we observed a cytotoxic effect for the compound 21 starting from 5 μM that decreased the cell viability to 50%. In contrast, compound 14 showed a good safety at all tested concentrations (Fig. 5A ). These data suggested that the inhibition of Kyn production by compound 21, observed along cellular screenings, was probably due to a decreased cellular viability rather than a specific inhibition of the catalytic activity of IDO1. For this reason, our study focused on molecule 14, hereafter indicated as VIS351, which demonstrated a safe profile in addition to a high CS score. We thus determined the IC 50 value of VIS351 by building a dose-response curve in the cellular assay. VIS351 was 3-fold diluted starting from its highest non-cytotoxic concentration (90 μM), whereas NLG919 was 3-fold diluted from 0.1 μM. The obtained curves of concentration provided a cellular IC 50 = 11.463 ± 6.323 μM and IC 50 = 0.013 ± 0.003 μM for VIS351 and the reference inhibitor NLG919, respectively (Fig. 5B) . In order to verify the specificity of the IDO1 inhibitory activity of VIS351, we tested the molecule in the same cell line stably expressing the mouse TDO, instead of IDO1. The cellular test demonstrated a dose-dependent inhibition of Kyn production by P1.IDO1 but not P1.TDO cells (Fig. 5C) . Next we performed a biochemical assay [30, 37] to determine the enzymatic IC 50 of VIS351 on the isolated recombinant IDO1 protein. We conducted the assay by using seven times 10-fold dilutions of the molecule, starting from the highest soluble concentration (2 mM). As expected, the reference inhibitor NLG919 showed a low enzymatic IC 50 = 0.518 ± 0.060 μM, whereas VIS351 did not inhibit the catalytic activity of the recombinant IDO1 at any tested concentrations (Fig. 5D) . Therefore and unexpectedly, we could not determine an enzymatic IC 50 for the novel compound, although the molecule had demonstrated a strong binding activity in MST experiments performed on the same protein target. The above observations suggested that, despite a strong binding of the IDO1 protein and inhibition of Kyn production by P1.IDO1 cells, VIS351 fails to act as a catalytic inhibitor of the recombinant IDO1 protein.
Binding mode of VIS351 molecule
In addition to the catalytic activity of IDO1, we previously identified and characterized a function of the protein mediated by two highly conserved ITIM-1 and ITIM-2 motifs, which, once phosphorylated, promote a fine modulation of the protein expression [20, 22] and confer a long-term immunoregulatory phenotype in different subsets of DCs [21, 38, 39] . Moreover, we demonstrated that the folding conformation of IDO1 necessary for mediating the ITIMs functions is not compatible with the one required for the catalytic activity, since the negative charge carried by phosphorylated tyrosines in ITIMs may affect the shape of the catalytic site. Therefore, a dynamic balance between the two IDO1 conformations that seem to be mutually exclusive may occur [23] . We thus applied a molecular docking to investigate the binding mode of VIS351, attempting to envisage any relationship between molecular interactions of the ligand into the catalytic pocket and the ITIM's tyrosines. Docking studies of this ligand into the catalytic cleft of IDO1 provided two solutions depicting similar binding poses with very similar energetical scores (solution #1: XPscore = −8.4 kcal/mol; 
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solution #2: XPscore = −8.2 kcal/mol) ( Fig. 6A and B) . In both solutions, VIS351 did not engage the heme group with hydrogen bonds and/or coordinative interactions, but only the two methyl groups of the indole moiety could make hydrophobic contacts with the porphyrin ring. Aromatic interactions were present between the indole moiety of this compound and the side chains of Tyr126, Phe163, Phe164, and Phe226 in both binding poses. Likewise, the terminal aromatic ring of VIS351 (14) was positioned close to Arg231, suggesting the formation of π-cation interactions. The difference between the two binding poses was determined by the polar group of the ligand engaging Gly262 in a hydrogen bond. In the first solution, the hydroxyl group of the central propanol scaffold interacted with the carbonyl group of Gly262. Conversely, the second solution showed the aniline nitrogen engaging Gly262 with a hydrogen bond. According to molecular docking results, it is worth noting that no direct interaction were observed between VIS351 and the ITIM's tyrosines (Tyr111, Tyr249), which are located 20 Å away from the center of mass of ligand (Fig. 6C) . However, the lack of a strong polar interaction between the molecule and the heme cofactor may bestow higher plasticity on the ligand-bound complex, allowing a conformational shift toward an ITIM-favoring form of IDO1 with the detriment of its enzymatically active conformation, thus resulting in Kyn reduction as we observed in the cellular assay. Embracing the hypothesis that the plasticity of VIS351-bound IDO1 could affect an ITIM-favoring conformation of IDO1, we next studied (14) and the center of mass of Tyr111 and Tyr249 residues, contained in ITIM-1 and ITIM-2 of IDO1 protein, respectively.
the effects of VIS351 on the ITIM-mediated functions of the enzyme.
VIS351 promotes the ITIM-mediated signaling activity of IDO1
We previously demonstrated that the ITIM-mediated activity of IDO1 can affect the half-life of the protein, by triggering the proteasomal degradation or the de novo synthesis of IDO1 as a consequence of the association of the phosphorylated IDO1's ITIMs with different protein partners, namely SOCS3 or SHP-1 and SHP-2 phosphatases, respectively [22] . We thus investigated whether VIS351 could affect either the ITIM-mediated mechanisms of IDO1. To this purpose, after protein translational inhibition by cycloheximide, we subjected P1.IDO1 cells to treatment for 0-6 h with 30 μM of VIS351 or DMSO, as control, and analyzed the expression of the IDO1 protein over time. As expected, we found a gradual reduction of β-tubulin-normalized IDO1 expression in the control lysates, reaching a decrease of 60% in 6 h. In a similar manner, the turnover of the IDO1 protein in VIS351-treated P1.IDO1 cells overlapped the pattern observed in the control, indicating that VIS351 may not affect the ITIM-mediated mechanism of the proteasomal degradation of IDO1 (Fig. 7A and B) .
We next investigated the modulation of IDO1 association with tyrosine phosphatases by VIS351, by evaluating the ability of IDO1 immunoprecipitates to remove a phosphate group from a tyrosine-phosphorylated substrate, as described [21, 23] . Specifically, we quantified the amount of free phosphate produced over 30 min by IDO1 immunoprecipitated from untreated and VIS351-treated P1.IDO1 cells. As previously shown [23] , we observed a basal phosphatase activity associated with IDO1 immunoprecipitates obtained from P1.IDO1 cells. However, preconditioning of P1.IDO1 cells with VIS351 for 4 h generated a significantly increased level of free phosphate at 20 min of the colorimetric reaction, as compared to control (Fig. 7C) , highlighting an interesting effect of VIS351 in promoting an alternative conformation of IDO1 suitable to acquire the capacity to interact with tyrosine phosphatases.
VIS351 confers an immunosuppressive phenotype on pDCs detectable in vivo
ITIM-related functions of IDO1 were firstly described in DCs, which are characterized by a plastic phenotype prompt to respond to whichever environmental signals [20, 21] . pDCs represent the most flexible DC subset that can shift from an immunostimulatory toward an immunosuppressive program for rapidly and efficiently sensing the extracellular milieu [40] . In order to better understand the biological relevance of VIS351, as a positive modulator of the signaling conformation of IDO1, we evaluated the in vivo priming ability of pDCs after in vitro conditioning with VIS351. Specifically, we sensitized female mice with the H-2D b -restricted HY peptide presented by a combination of immunogenic cDCs and a minority fraction of pDCs preincubated in vitro overnight with VIS351 or DMSO, as control. Two weeks later, we evaluated the antigen-specific reactivity through an intrafootpad challenge of the HY antigen, according to an established protocol for measuring the induction of immune reactivity versus tolerance [41] [42] [43] [44] . As expected, sensitization of mice with a combination of immunogenic cDCs and vehicle-treated pDCs elicited a positive response against the HY antigen in mice. In contrast, VIS351-pretreated pDCs abrogated the immunoadjuvant response elicited by cDCs, suggesting that VIS351 could induce in pDCs a tolerogenic phenotype. Moreover, preconditioning of Ido1 −/− pDCs with VIS351 in the same in vivo assay negated the tolerogenic properties in pDCs that evidently would require an intact IDO1 protein to mediate VIS351-induced immunosuppression in vivo (Fig. 8A) . We previously demonstrated that the ITIM-mediated signaling activity of IDO1 in pDCs triggers a positive loop culminating in a late E. Albini et al. Biochemical Pharmacology 158 (2018) 286-297 induction of the immunoregulatory cytokine TGF-β and the IDO1 itself, both responsible for a long-term immunoregulatory phenotype of the pDCs [21, 31, 45] . Thus, in pDCs treated with VIS351, we monitored over time the gene transcription of key molecules involved in such selfmaintaining regulatory circuitry, including Ido1, Tgfb1 (coding for the immunoregulatory cytokine TGF-β), Ptpn6 and Ptpn11 (coding for SHP-1 and SHP-2 phosphatases, respectively). We did not observe any early induction of the examined genes in the first 6 h of pDC stimulation with VIS351, but we did detect a late induction of the above genes after 16 h of stimulation. Conversely, expression of Socs3 in the same cells was not affected by VIS351 treatment at any time points, thus excluding the occurring of the alternative ITIM-mediated function of IDO1 that leads to its proteasomal degradation [20, 22] (Fig. 8B) .
A late gene induction of the molecular players participating in the signaling activity of IDO1 suggested that VIS351 may indirectly promote the induction of such molecules, by favoring a conformation of the IDO1 protein suitable for the activation of the ITIM-mediated signaling mechanism, as already suggested by the cellular and the enzymatic screenings. In addition, VIS351 also induced a significantly increased level of the immunoregulatory cytokine TGF-β but not of the proinflammatory cytokine IL-6 which drives the ITIM-mediated proteasomal degradation of IDO1 [20] . Nor IL-10 ( Fig. 8C) neither TNF-α or IFN-α (data not shown) levels were affected by VIS351 in pDCs, suggesting a priority role of the immunoregulatory cytokine TGF-β in the VIS351-induced activity of IDO1 protein. More interestingly, VIS351 significantly induced the secretion of Kyn in pDCs (Fig. 8D) , possibly representing a downstream event triggered by activation of the signaling function of IDO1 that can induce its own expression in pDCs, thus promoting a tolerogenic phenotype in the cells [21] .
By cytofluorometric analysis of popliteal lymph node cells (i.e., draining antigen-challenged footpads), we found that the abrogation of skin test reactivity elicited by VIS351-treated pDCs was accompanied by significantly decreased frequencies of IFN-γ-producing CD8 + and CD4 + T cells (Fig. 8E) , when compared to the control group with detectable skin reactivity. A significant increase of CD4 + T cells expressing surface TGF-β in its LAP form and the transcription factor Foxp3 as well as of IL-10-producing CD4 + T cells was also found (Fig. 8F) .
Overall, the phenotypic characterization of the main T cell subsets populating the antigen-draining lymph nodes of mice sensitized with VIS351-treated pDCs suggested the possible instauration of an immunoregulatory microenvironment that would oppose the migration of IFN-γ−producing CD8 + and CD4 + T cells.
Thus activation of the ITIM-based signaling function of IDO1 by VIS351 in pDCs may trigger a self-maintained immunoregulatory E. Albini et al. Biochemical Pharmacology 158 (2018) [286] [287] [288] [289] [290] [291] [292] [293] [294] [295] [296] [297] circuitry in vivo where TGF-β plays a dominant role during the antigenspecific immune response. TGF-β may be indeed at work in the afferent phase of sensitization by VIS351-treated pDCs, which secrete higher levels of TGF-β, and also in the later efferent phase of antigen recalling response, where regulatory T cell would contribute to maintain high the levels of the cytokine.
Discussion
Since its identification as a critical enzyme in cancer's evasion of immune responses [46] , drug discovery efforts have been intensively pursued to develop effective and selective catalytic inhibitors of IDO1. IDO1 is now considered an immune checkpoint molecule [47] and thus IDO1 targeting has become an attractive approach in immuno-oncology. Differently from immune checkpoint receptors (i.e., CTLA-4 and PD-1) expressed on the cell membrane and easily accessible by specific antibodies, IDO1 is an intracellular enzyme, best druggable by small molecules. To date, the majority of IDO1-specific molecules acts as competitive or noncompetitive inhibitors, by either mimicking the tryptophan substrate or by binding the heme cofactor, respectively [48] . Although IDO1 inhibitors are largely recognized as powerful 'immunometabolic adjuvants' to enhance anti-tumor immune responses-at least in preclinical models [49] -epacadostat recently showed disappointing efficacy in cancer's patients in combination with pembrolizumab, an anti-PD-1 antibody [50, 51] . As a consequence of this failure, other clinical trials with IDO1 inhibitors have been suspended, canceled, or downsized. Although several reasons may explain epacadostat's results, further studies on the basic biology of the enzyme may be mandatory to unravel the complex IDO1-driven immunoregulatory network.
In addition to impairing immune effector functions via tryptophan starvation, IDO1 (and TDO) catalyzes the formation of Kyn that also mediates tumor immune escape mechanisms via activation of AhR. Interestingly, Liu Y et al. recently identified a Kyn-AhR-dependent mechanism upregulating PD-1 in tumor-specific cytotoxic T lymphocytes and thus promoting immune escape [52] . These data would support the rationale of combining IDO1 inhibitors with PD-1-specific antibodies. Nevertheless, the failure of phase III trial with Incyte's epacadostat and Merck & Co's pembrolizumab would suggest the existence of additional causes impairing therapeutic efficacy. A confounding factor of this history is the recent observation that some IDO1 inhibitors (i.e., epacadostat and NLG919A) bind the AhR and, on their own, could suppress the immune system, thus inducing the opposite outcome of the drug's intent [53] . How much such 'off-target' effects may reverberate on the anti-tumor efficacy of IDO1 inhibitors is still unclear. However, it should be kept into consideration for the optimization of pharmaceutical properties of this class of drugs.
A further grade of complexity in considering IDO1 as a drug target consists in its 'moonlighting' feature that confers a unique multi-tasking functional profile. Two different activities reside in the monomeric IDO1 protein, i.e., the well-characterized catalytic function that requires the heme cofactor in the large domain of the protein [25] and the most recent signaling function of IDO1 requiring the tyrosine-phosphorylation of ITIM-1 and ITIM-2 motifs located in the small domain [20, 21] . Major conformational changes may occur in IDO1 protein in order to expose ITIM's phosphorylable tyrosines and activate the ITIMmediated activity. The negative charge carried by phosphorylated tyrosines of ITIMs may affect the shape of the catalytic site, so that the ITIM-favoring conformation would exclude the catalytic active form of IDO1 [23] . The characterization of VIS351 as a modulator of the ITIMmediated signaling of IDO1, rather than its catalytic activity, identifies for the first time a molecule acting on the non-enzymatic activity of IDO1 and paves the basis for a novel screening approach of molecules targeting the ITIM functions of IDO1. On one hand, because IDO1 catalytic inhibitors have failed in cancer clinical setting, the molecular dissection of the ITIM signaling pathway in DCs may provide further therapeutic opportunities to make IDO1 protein an effective drug target. On the other hand, reinterpreting the clinical failure of IDO1 inhibitors under the lens of the ITIM-mediated signaling in DCs may suggest innovative immunotherapeutic combinations. In fact, it should be underlined that the IDO1 ITIM-mediated signaling sustains a longterm immunoregulatory circuitry in DCs that may restrain abnormal immune responses [31] . Beyond its role as immune checkpoint inhibitor to be blocked in cancer, IDO1 could be conversely exploited in a variety of immune disorders, including autoimmune diabetes [47] , where the enzyme has been demonstrated to be defective in both the preclinical models [11, 15] and the human disease [54, 55] . To date, positive modulators of IDO1 (i.e., catalytic enhancer as well as allosteric modulators of IDO1 signaling) are lacking and therefore, VIS351 may represent an important compound capable of bridging such gap.
Overall, the dual regulatory function of IDO1, as a catalyst and a signaling molecule, makes this protein a fascinating immunotherapeutic target. Positive modulators of the ITIM-mediated activity of IDO1 may come as a breath of fresh air in IDO1-based drug discovery.
